Photocure ASA (PHO) NOK0.5
Sell:51.00 NOKBuy:54.50 NOK
0.70 NOK
(1.33%)
- This stock can be held in a
Stocks and Shares ISA0.70 NOK
(1.33%)0.70 NOK
(1.33%)Company Information
About this company
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Key people
Key facts
- EPICPHO
- LocationNorway
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINNO0010000045
- Market capNOK 1.43bn
- Employees102
- Shares in issue27.12m
- ExchangeOslo Stock Exchange
- IndexOSL All-share Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.